PRKAA1 and Alzheimer disease: Studies have demonstrated that the reduction of AMP-activated protein kinase (AMPK) could result in progressive loss of neuronal functions, suggesting that restoration of AMPK expression may serve as a potential therapeutic target for AD (Yang et al., 2015).